PLoS ONE · 2014 · 59 citations · 19 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyMolecular OncologyAngiogenesisAngiogenesis In CancerKidney CancerRenal Cell CarcinomaTargeted Cancer TherapyTyrosine Kinase InhibitorsTherapeutic Growth InhibitionTumor Angiogenesis SignalingTyrosine Kinase Inhibitor TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor Pathway ModulationVegf Pathway Inhibition
BACKGROUND: The Notch ligand Delta-like 4 (Dll4) is highly expressed in vascular endothelium and has been shown to play a pivotal role in regulating tumor angiogenesis. Blockade of the Dll4-Notch pathway in preclinical cancer models has been associated with non-productive angiogenesis and reduced tumor growth. Given the cross-talk between the vascular endothelial growth factor (VEGF) and Delta-Notch pathways in tumor angiogenesis, we examined the activity of a function-blocking Dll4 antibody, REGN1035, alone and in combination with anti-VEGF therapy in renal cell carcinoma (RCC). METHODS AND RESULTS: Severe combined immunodeficiency (SCID) mice bearing patient-derived clear cell RCC xenografts were treated with REGN1035 and in combination with the multi-targeted tyrosine kinase inhibitor sunitinib or the VEGF blocker ziv-aflibercept. Immunohistochemical and immunofluorescent analyses were carried out, as well as magnetic resonance imaging (MRI) examinations pre and 24 hours and 2 weeks post treatment. Single agent treatment with REGN1035 resulted in significant tumor growth inhibition (36-62%) that was equivalent to or exceeded the single agent anti-tumor activity of the VEGF pathway inhibitors sunitinib (38-54%) and ziv-aflibercept (46%). Importantly, combination treatments with REGN1035 plus VEGF inhibitors resulted in enhanced anti-tumor effects (72-80% growth inhibition), including some tumor regression. Magnetic resonance imaging showed a marked decrease in tumor perfusion in all treatment groups. Interestingly, anti-tumor efficacy of the combination of REGN1035 and ziv-aflibercept was also observed in a sunitinib resistant ccRCC model. CONCLUSIONS: Overall, these findings demonstrate the potent anti-tumor activity of Dll4 blockade in RCC patient-derived tumors and a combination benefit for the simultaneous targeting of the Dll4 and VEGF signaling pathways, highlighting the therapeutic potential of this treatment modality in RCC.
19
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Irene Noguera‐Troise, Christopher Daly, Nicholas Papadopoulos et al. · Nature · 2006 · 1K citations
Medicine, Cancer Biology, Oncology +14
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
John Brady Ridgway, Gu Zhang, Yan Wu et al. · Nature · 2006 · 982 citations
Medicine, Cancer Biology, Oncology +12
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Christian Fischer, Bart Jonckx, Massimiliano Mazzone et al. · Cell · 2007 · 788 citations · Full text
Medicine, Oncology, Pharmacology +14
DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
Timothy Hoey, Wan-Ching Yen, Fumiko Axelrod et al. · Cell stem cell · 2009 · 397 citations · Full text
Medicine, Cancer Biology, Oncology +14